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LATENT CLASSES OF NONRESPONDERS, RAPID
RESPONDERS, AND GRADUAL RESPONDERS IN
DEPRESSED OUTPATIENTS RECEIVING
ANTIDEPRESSANT MEDICATION AND
PSYCHOTHERAPY
Michel A. Thibodeau, M.A.,1∗ Lena C. Quilty, Ph.D.,2,3 Filip De Fruyt, Ph.D.,4 Marleen De Bolle, Ph.D.,4
Fre´de´ric Rouillon, M.D.,5 and R. Michael Bagby, Ph.D.2,3,6
Background: We used growth mixture modeling (GMM) to identify subsets of
patients with qualitatively distinct symptom trajectories resulting from treat-
ment. Existing studies have focused on 12-week antidepressant trials. We used
data from a concurrent antidepressant and psychotherapy trial over a 6-month
period. Method: Eight hundred twenty-one patients were randomized to receive
either fluoxetine or tianepine and received cognitive-behavioral therapy, sup-
portive therapy, or psychodynamic therapy. Patients completed the Montgomery–
A˚sberg depression rating scale (MADRS) at the 0, 1, 3, and 6-month periods.
Patients also completedmeasures of dysfunctional attitudes, functioning, and per-
sonality. GMM was conducted using MADRS scores and the number of growth
classes to be retained was based on the Bayesian information criterion. Results:
Criteria supported the presence of four distinct latent growth classes represent-
ing gradual responders of high severity (42% of sample), gradual responders of
moderate severity (31%), nonresponders (15%), and rapid responders (11%).
Initial severity, greater use of emotional coping strategies, less use of avoidance
coping strategies, introversion, and less emotional stability predicted nonrespon-
der status. Growth classes were not associated with different treatments or with
proportion of dropouts. Conclusions: The longer time period used in this study
highlights potential overestimates of nonresponders in previous research and the
need for continued assessments. Our findings demonstrate distinct growth tra-
jectories that are independent of treatment modality and generalizable to most
psychotherapy patients. The correlates of class membership provide directions
for future studies, which can refine methods to predict likely nonresponders as
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INTRODUCTION
The designation treatment responder is the prevail-
ing term for a patient who has beneﬁted substantially
from treatment. This classiﬁcation is common in clini-
cal settings as it can inform whether treatment should
be terminated, continued, or modiﬁed. It is similarly
common in research settings, wherein the proportion
of treatment responders is used as an index of efﬁcacy.
Deﬁnitions of treatment response vary, but typically in-
volve a relative reduction in symptoms (e.g. 50% reduc-
tion) and/or a reduction in symptoms below an absolute
threshold of severity (e.g. scoring under eight on the
Hamilton Depression Rating Scale).[1] Existing research
suggests that responses to depression treatments vary
markedly across individuals. For example, as many as
50% of patients receiving antidepressants can be clas-
siﬁed as nonresponders.[2–4] Moreover, a minority of
patients (15%)may be rapid-responders, beneﬁting sub-
stantially from only 2 weeks of antidepressants.[3,5] Sim-
ilar rates of nonresponders and rapid responders appear
in psychotherapy research.[6–8]
The ability to classify patients as likely responders or
nonresponders would be remarkably useful to clinical re-
search and practice andwould represent a crucial step to-
ward effective personalizedmedicine. For example, rapid
responders could be offered abbreviated therapy, gradual
responders could be offered usual treatment, and non-
responders could be offered enhanced treatment. Simi-
larly, researchers could explore the efﬁcacy of aggressive
treatments in expected nonresponders and of relatively
cost-effective treatments in expected rapid responders.
A great deal of research has thus focused on discover-
ing predictors of nonresponse in depression treatments,
such as biomarkers,[9] initial severity,[10] dysfunctional
attitudes,[11] cooccurrence of other mental disorders,[12]
and personality traits[13]; however, the utility of classify-
ing nonresponders is only proportional to the validity of
how a nonresponder is deﬁned.
A contemporary method of statistical modeling,
known as growth mixture modeling (GMM), can shed
light on the latent nature of treatment responses. GMM
identiﬁes whether there are subsets of individuals whose
growth trajectories are qualitatively dissimilar from that
of others. For example, GMM can test whether data are
best conceptualized as including one growth trajectory
(e.g. most patients experience gradual improvement) or
as encapsulating unobserved subpopulations with dis-
tinct growth trajectories. Use of GMM can thus evade
the traditional and relatively arbitrary deﬁnitions of non-
response (e.g. 50% reduction is a response but not 49%),
thereby increasing the validity of classiﬁcation and of
predictors of class membership. A total of ﬁve stud-
ies have applied GMM in antidepressant trials,[5,14–16]
with one of these studies also including psychotherapy
as a concurrent treatment with medication.[17] All ﬁve
studies supported the presence of distinct latent growth
classes. Three out of the ﬁve studies supported the pres-
ence of distinct nonresponder and responder classes, one
demonstrated responder and rapid responder classes,
while results of the ﬁfth study (including psychother-
apy) supported three classes of varying severity, but with
similar slopes of change.
Despite advances in this ﬁeld, there exist two salient
areas in need of research. First, existing studies have in-
cluded trials of only 12 weeks. The limited time frames
of existing studies may obfuscate important features of
growth trajectories. For example, nonresponders may
reach standards of response during typical administra-
tions of antidepressants (which go beyond 12 weeks), or
some responders at 12weeksmay lose their gains and be-
come nonresponders in the longer term. Second, there
is a lack of research exploring growth trajectories in psy-
chotherapy patients. The single study that has explored
this matter,[17] while informative, does not generalize
well to most settings. The study included only patients
with chronic depression lasting over 2 years, made use of
a patented and specialized form of psychotherapy (cog-
nitive behavioral analysis system of psychotherapy, not
to be confused with cognitive behavioral therapy), and
included growth slopes ﬁxed between sessions, preclud-
ing conclusions regarding when change occurred.
The current study was designed to address these gaps
in existing research.We explored latent growth classes in
individuals receiving antidepressants and participating in
common forms of psychotherapy over 6 months. Based
on previous research, we expected to identify three dis-
tinct classes, namely nonresponders, gradual responders,
and rapid-responders. We also replicated our analyses
using data up to only 12 weeks to compare our ﬁndings
to previous research and to determine the impact of in-
cluding data over a period of 6months. Furthermore, we
explored whether preexisting factors (e.g. personality di-
mensions) predicted class membership. These analyses
were deemed exploratory and were not associated with
a priori hypotheses.
METHODS
PATIENTS AND TREATMENT
Outpatients were recruited from psychiatric centers in 25 re-
gions near Paris to participate in a multicenter randomized
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double-blind study exploring the efﬁcacy of two medications (ﬂu-
oxetine [20 mg/day] and tianepine [50 mg/day]) and three forms of
psychotherapy (cognitive-behavioral therapy, supportive therapy, and
psychodynamic therapy). Eight hundred twenty-one individuals par-
ticipated andwere eligible by presentingwithmoderate or severemajor
depressive disorder based on criteria of the diagnostic and statistical
manual ofmental disorders (DSM-IV)[18] and scores of 20 or higher on
theMontgomery–A˚sberg depression rating scale (MADRS).[19] Exclu-
sion criteria included present or past psychosis, resistance to two previ-
ous pharmacological interventions, hospitalization for electroconvul-
sive therapy, or a history of drug or alcohol abuse. Patients were also
excluded if they were previously treated with an antidepressant in the
15 days before participating, had undergone one of the three methods
of psychotherapy in the previous year, or had failed a previous trial of
either study medication. Inclusion and exclusion criteria were estab-
lished by unstructured interviews and chart reviews conducted by the
psychiatrists providing treatment. The majority (68.2%) of patients
were women and ages ranged from 18 to 66 (mean = 39.74, SD =
10.61).
Four hundred twenty-four patients were randomized to receiv-
ing ﬂuoxetine and 397 were randomized to receiving tianepine. Psy-
chotherapy modalities were not randomized; rather, a patient’s psy-
chotherapy condition was based on the orientation of the psychiatrist
performing the psychotherapy. Two hundred thirty-three (28.4%),
326 (39.6%), and 262 (31.9%) participants received psychotherapy
from psychiatrists describing their orientation as cognitive-behavioral,
supportive, and psychodynamic, respectively. Four patients (<1%)
dropped out within one month, 86 (10%) patients dropped out within
3 months, and 136 (17%) patients dropped out within 6 months. Pro-
portion of dropouts was not associated with type of medication (χ2 =
.80, df = 1, P > .30) or mode of psychotherapy (χ2 = .24, df = 1, P >
.80). The study procedures were approved on ethical grounds by the
Institutional Review Board of l’Institut de Recherches Internationales
Servier and by the Comite´ Consultatif de Protection des Personnes
dans la Recherche Biome´dicale and complied with the Declaration of
Helsinki and the Good Clinical Practice Guidelines.
MEASURES
The MADRS[19] was used to assess depression symptoms and to
estimate latent growth classes. The MADRS is a 10-item clinician-
rated instrument and a score of 10 (inclusive) has been demonstrated
as the optimal cut-off for nonresponder status in depression trials.[20]
Clinician-rated MADRS scores have been demonstrated as correlat-
ing very highly (>.80) with self-report MADRS scores.[21] MADRS
scores exhibited good to excellent internal consistency at all time points
(αs = .76, .87, .89, and .91).
The following secondary measures were included to characterize
the latent growth classes. The single-item clinician-rated global assess-
ment of functioning (GAF)[18] and clinical global impression (CGI)[22]
scales were included to assess pretreatment functioning and severity.
The dysfunctional attitude scale (DAS),[23] which includes 40 items,
was included to assess the severity of preexisting cognitive distortions
based on Beck’s cognitive model of depression. The coping inventory
for stressful situations (CISS)[24] was included to assess preferred cop-
ing styles of patients. The CISS includes 61 items describing how indi-
viduals react toward difﬁcult situations and assesses proclivities toward
task-oriented (e.g. focusing on the problem), emotion-oriented (e.g.
feeling angry), and avoidance-oriented coping strategies (e.g. being
with others). Higher scores reﬂect a greater tendency to use a partic-
ular coping strategy. Patients also completed the Syste`me de Descrip-
tion en Cinq dimensions (D5D),[25] which includes 55 items assessing
dimensions of the ﬁve factor personality model, namely openness to
experiences, conscientiousness, introversion, agreeableness, and emo-
tional stability (neuroticism).Higher scores on subscales reﬂect greater
levels of the personality traits. Item-level scores were not available for
the secondary measures.
ANALYSES
GMM was conducted using Latent Gold 4.5.1 MADRS scores at
month 0, month 1, month 3, andmonth 6, were used to estimate latent
growth classes. Sixmodelswere tested, reﬂectingmodelswith one to six
latent growth classes.Model selection was based on the Bayesian infor-
mation criterion (BIC) and the consistent Akaike information criterion
(CAIC).[26,27] The model with the lowest BIC and CAIC values was
retained. BIC valueswould be given priority in case of a discrepancy be-
tween the indices.[26] Modalities of therapy and medication types were
not speciﬁed in the models. This allowed the potential growth classes
to vary freely across treatment groups and identiﬁcation of whether
treatment groups are associated with different growth classes. The six
models were tested twice, once without covariates, and a second time
with demographic covariates. Demographic covariates included age,
sex, education level, marital status, and employment status. Individual
heterogeneity within the classes was captured by estimating random
effects.
A chi-square test examined whether individuals within different
treatment groups exhibited varying odds of belonging to different
growth classes. A series of one-way analyses of variance tested whether
patients in different growth classes scored differently on variables at in-
take. Post-hoc analyses (Tukey) tested for differences between pairs of
classes. Two chi-square tests examined whether individuals in different
growth classes had varying odds of presenting with a cooccurring Axis I
disorder or personality disorder.Multinomial logistic regressions were
also conducted to determine whether intake variables predict growth
classes. Three regressions were conducted using thematically similar
predictors. The ﬁrst regression included MADRS, CGI, GAF, and
DAS scores, the second included the three CISS scales, and the third
included the ﬁve D5D scales.
Lastly, our GMM analyses were repeated using data up to only
the 12-week time point. These analyses would allow us to determine
how use of a longer 6-month time period inﬂuences the estimation of
latent growth classes, their relative proportions, and the nature of their
growth trajectories.
RESULTS
IDENTIFYING LATENT GROWTH CLASSES
BIC and CAIC values for tested models supported the
presence of four latent classes based on the GMM using
covariates (Table 1). The classes represented 42, 31, 16,
and 11% of the sample. The growth trajectories are dis-
played in Fig. 1. Patients in the ﬁrst and largest class
experienced on average a 70% reduction in symptoms
during treatment. Patients in this class presented with
an average MADRS score of 32.12 (SD = 5.06) at in-
take and approximately 40% of patients scored over 10
on the MADRS at 6 months. For the purposes of this
report, this class is characterized as “gradual responders
(severe).” Patients in the second class experienced on
average an 80% reduction in symptoms during treat-
ment. Patients in this class presented with an average
1The term latent class growth modeling is preferred by the creators of
the Latent Gold software; however, “latent class model” and “mixture
model” are synonymous. We use the term GMM to be consistent with
existing research in this area.
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TABLE 1. Model selection criteria for models with different number of latent growth classes
Selection criteria Proportion of patients with each class
Without covariates BIC CAIC 1 2 3 4 5 6
1 class 20,580 20,585 100%
2 classes 19,826 19,837 54% 46%
3 classes 19,620 19,637 42% 29% 29%
4 classes 19,527 19,550 44% 30% 16% 11%
5 classes 19,467 19,496 29% 26% 16% 15% 13%
6 classes 19,442 19,477 22% 22% 19% 18% 15% 4%
With covariates BIC CAIC
1 class 19,816 19,821 100%
2 classes 19,178 19,204 53% 47%
3 classes 19,062 19,109 43% 29% 28%
4 classes 19,041 19,109 42% 30% 16% 11%
5 classes 19,074 19,163 31% 24% 18% 16% 12%
6 classes 19,155 19,265 27% 21% 18% 17% 10% 8%
Notes: BIC, Bayesian information criterion; CAIC, consistent Akaike information criterion; lowest values indicate best ﬁt and are in bold.
Figure 1. Symptom trajectories of individual patients within each of the growth classes. Bolded lines represent the mean growth
trajectory for that class. Y-Axis values represent total Montgomery–A˚sberg depression rating scale scores.
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TABLE 2. ANOVA results and differences between growth classes on intake variables
(1) Gradual (2) Nonresponders (3) Rapid F 2 vs. 1 (d) 3 vs. 1 (d) 2 vs. 3 (d)
Intake MADRS 29.91 (5.14) 33.21 (5.55) 30.44 (5.33) 18.86** .62 — .51
Intake CGI 4.87 (.59) 5.08 (.58) 4.94 (.58) 6.05** .36 — —
Intake GAF 53.76 (9.54) 50.22 (8.34) 56.06 (8.35) 9.87** −.40 — −.70
Dysfunctional attitudes 164.37 (34.25) 175.04 (37.17) 154.76 (33.99) 7.73** .30 — .57
Emotional coping 55.42 (10.18) 57.61 (10.39) 51.07 (12.39) 8.40** — −.39 .57
Task coping 49.11 (11.36) 48.24 (14.25) 54.29 (10.67) 7.01** — .47 −.49
Avoidance coping 42.32 (11.33) 39.23 (12.10) 45.84 (13.18) 6.75** −.26 .29 −.52
Introversion 43.76 (9.48) 47.65 (9.51) 42.74 (8.81) 8.30** .41 — .54
Agreeableness 45.38 (8.17) 45.4 (8.43) 48.26 (7.28) 4.53* — .37 −.36
Conscientiousness 47.76 (9.89) 47.26 (10.00) 48.41 (8.51) 0.31 — — —
Emotional stability 29.39 (8.64) 27.18 (9.54) 32.22 (9.24) 7.29** — .32 −.54
Openness to experiences 41.64 (8.93) 38.87 (11.24) 44.21 (9.04) 7.46** −.27 — −.53
Notes: ∗∗P < .01; ∗P < .05; cells with a hyphen indicate group differences that did not reach statistical signiﬁcance in the post hoc test (P > .05);
standard deviations in parentheses; d–Cohen’s d; MADRS, Montgomery–A˚sberg depression rating scale; CGI, clinical global impression; GAF,
global assessment of functioning.
MADRS score of 26.97 (SD= 3.51) at intake and approx-
imately 5% of patients scored over 10 on the MADRS
at 6 months. This class is characterized as “gradual re-
sponders (moderate).” Patients in the third class experi-
enced on average a 33% reduction in symptoms during
treatment. Patients in this class presented with an aver-
age MADRS score of 33.21 (SD = 5.51) at intake and
100% of patients in this class scored over 10 on the
MADRS at 6 months. Patients within this class shared
markedly different growth trajectories and, generally
speaking, did not fare well in treatment. This class is
characterized as “nonresponders.” Patients in the fourth
class experienced on average an 88% reduction in symp-
toms during treatment. Of note, patients in this class
experienced on average a 75% reduction in symptoms
by the ﬁrst month. Patients in this class presented with
an average MADRS score of 30.44 (SD = 5.30) at in-
take and 0% of patients in this class scored over 10 on
the MADRS at 6 months. This class is characterized as
“rapid responders.”
Model ﬁt criteria best supported the presence of four
latent growth classes, but the gradual responders (severe)
and gradual responders (moderate) classes shared similar
growth trajectories and differedmostly in overall severity
(see Fig. 1).2 Given our focus on preexisting factors pre-
dicting treatment trajectories, rather than initial severity,
the two gradual responder groups were combined for
subsequent analyses. This allowed more interpretable
and parsimonious conclusions and conforms with rec-
ommendations in interpreting latent classes.[28,29]
PREEXISTING DIFFERENCES BETWEEN
CLASSES AND PREDICTING CLASS MEMBERSHIP
The one-way analyses of variance identiﬁed group dif-
ferences on most intake indices, including intake de-
2A repeated-measures analysis of variance supported differences in pre-
senting severity (i.e., MADRS, CGI, and GAF scores) and also sup-
ported the relative parallelism (i.e., slope proﬁles) of the two gradual
growth trajectories (ηg2 <.01).
pression symptoms, clinical global impression scores,
global assessment of functioning ratings, dysfunctional
attitudes, emotion-oriented coping, task-oriented cop-
ing, avoidance-oriented coping, introversion, agreeable-
ness, emotional stability, and openness to experiences.
Means on these scores and results of the post-hoc tests
are included in Table 2.
The predictors of group membership included in the
multinomial logistic regressions are included in Table 3.
Intake depression scores predicted nonresponder status
relative to gradual responder status and global assess-
ment of functioning ratings and dysfunctional attitudes
predicted nonresponder relative to rapid-responder sta-
tus.Greater emotional coping tendencies predicted non-
responder status relative to both gradual and rapid re-
sponder status and lower avoidance coping predicted
nonresponder status relative to both gradual and rapid
responder status. Greater introversion and lower emo-
tional stability both predicted nonresponder status rela-
tive to gradual and rapid responder statuses.
Growth classes did not exhibit different proportions
of individuals with a cooccurring Axis I disorder (χ2 =
3.67, df = 2, P > .15), but growth classes had differ-
ent proportions of individuals with a personality disor-
der (χ2 = 17.62, df = 2, P < .001). Individuals from
the nonresponder class had 43% greater risk of having a
personality disorder compared to the gradual responder
class (risk ratio = 1.43 [95% CI = 1.20–1.70]) and 84%
greater risk compared to the rapid responder class (risk
ratio = 1.84 [95% CI = 1.32–2.57]). The gradual and
rapid-responder classes did not seem to differ in terms
of proportion of individuals with a personality disorder
(risk ratio = 1.29 [95% CI = 0.94–1.76]).
GROWTH CLASSES AND TREATMENT GROUPS
AND PATIENT DROP OUTS
Treatment groups were not associated with member-
ship in growth classes (χ2 = 9.93, df = 10, P > .40).
Moreover, proportion of dropouts was not associated
with latent growth classes (χ2 = 4.04, df = 2, P > .10).
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TABLE 3. Independent predictors of class membership resulting from three multinomial logistic regressions
Gradual responders Rapid responders
B SE Wald B SE Wald
1. Initial severity variables
Intercept 4.21 1.51 7.77** −0.25 1.94 0.02
Intake MADRS −0.08 0.03 10.89** −0.06 0.03 3.15†
Intake CGI 0.01 0.24 <0.01 0.39 0.32 1.48
Intake GAF 0.02 0.01 2.65 0.05 0.02 9.01**
Dysfunctional attitudes −0.01 0.00 3.21† −0.02 0.01 11.89**
2. Coping strategies
Intercept 2.05 0.88 5.42* −0.64 1.24 0.27
Emotional coping −0.03 0.01 4.66* −0.06 0.02 13.70**
Task coping 0.00 0.01 0.06 0.03 0.01 3.36†
Avoidance coping 0.03 0.01 7.66** 0.05 0.01 13.13**
3. Personality dimensions
Intercept 2.55 1.03 6.08* −1.97 1.44 1.87
Introversion −0.05 0.02 10.15** −0.06 0.02 7.98**
Agreeableness −0.01 0.02 0.79 0.02 0.02 1.05
Conscientiousness 0.01 0.01 0.33 0.00 0.02 0.00
Emotional stability 0.04 0.01 8.51** 0.07 0.02 13.73**
Openness to experiences 0.01 0.01 0.74 0.03 0.02 2.28
Notes: The reference category is the nonresponder class; †P < .10, ∗P < .05, ∗∗P < .01; MADRS, Montgomery–A˚sberg depression rating scale;
CGI, clinical global impression; GAF, global assessment of functioning.
IDENTIFYING LATENT GROWTH CLASSES
USING OUTCOMES UP TO 12 WEEKS
GMM using only three time points supported the
presence of three latent growth classes (BIC for 1, 2,
3, and 4 classes = 15,267; 14,923; 14,911; 14,943, re-
spectively). The classes represented 46, 41, and 13%
of patients. The three classes differed from those
observed using the four time points.The third and small-
est class was similar to the rapid responder class result-
ing from the ﬁrst analyses, with patients experiencing on
average an 88% reduction in symptoms and 0% of pa-
tients reporting a score of 10 or higher on the MADRS
at the third time point. In contrast, a nonresponder class
was not present in the second GMM analyses. Instead,
the two remaining classes can be described generally as
gradual responders, but these gradual responders faired
poorly compared to those identiﬁed in the previous anal-
ysis. The classes experienced 45 and 65% reductions in
symptoms (compared to 70 and 80% for the gradual re-
sponders in the previous analysis) with 88 and 35% of
patients scoring higher than 10 on the MADRS at the
3-month point (compared to 40 and 5% at the 6-month
point). In essence, the nonresponders described when
using the four time points were amalgamated into the
two gradual responder classes obtained from using the
shorter time period.
DISCUSSION
We examined growth trajectories in depressed indi-
viduals participating in 6months of antidepressant treat-
ment and psychotherapy. Our results add to existing
studies supporting the presence of distinct trajectories
of patient responses to depression treatments.[5,14–17] We
identiﬁed four latent growth classes that occurred nat-
urally in our data. The ﬁrst two classes included in-
dividuals who reported gradual changes in treatment,
the third class included individuals who generally did
not respond well to treatment, and the fourth class
included individualswho responded very rapidly to treat-
ment (i.e. within 4 weeks).
Overall, the majority of patients (approximately 85%)
belonged to a class exhibiting a signiﬁcant reduction
in symptoms. In other words, the treatments were at
least moderately effective for most patients, even if pa-
tients varied markedly in presenting severity. Generally
speaking, the gradual change classes reported continued
decreases in symptoms until the 6-month point. The
continued change is exempliﬁed in the gradual respon-
ders (severe) class, such that mean scores declined from
15 to 9 between the 3 and 6-month periods (Fig. 1).
Moreover, the rapid responder class maintained its early
gains throughout the entire treatment. These patterns
subsequent to the 12-week point highlight the impor-
tance of longer term assessments in this ﬁeld. Contin-
ued symptom decline suggests that shorter trials might
greatly underestimate the proportion of responders in
typical treatment settings, and that nonresponders may
reach standards of response after continued treatment.
Indeed, our analyses using only 12 weeks of data did
not demonstrate an independent nonresponder class,
but rather supported two gradual responder classes with
relatively poor outcome. The longer time period al-
lowed differentiation between individuals who meet a
substantial level of nonresponse compared to those who
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responded gradually and substantially over time. These
results thus highlight the importance of using treatment
periods more typical of real-world applications, partic-
ularly if using strict cut-off scores (e.g. scoring less than
10 on the MADRS).
Our ﬁndings support previous research demonstrat-
ing rapid responders to depression treatments.[6–8]
Preliminary research suggested that sudden gains in de-
pression treatments may represent a placebo effect,[30]
but more recent analyses of medication and psychother-
apy trials with placebo controls suggest that sudden
gains are likely attributable to pharmacological and psy-
chotherapeutic agents.[31,32] Additionally, our ﬁndings
are the ﬁrst to demonstrate that nonresponders and rapid
responders in psychotherapy represent unique classes
with change trajectories warranting distinction. We be-
lieve our ﬁndings generalize well to naturalistic psy-
chotherapy treatments given that most clients are also
prescribed antidepressants.[33,34] Growth class member-
ship was not associated with type of medication or the
psychotherapeutic orientation of the psychiatrists, sug-
gesting that preexisting factors associated with nonre-
sponder status may have played a larger role in observed
treatment outcomes than the actual type of treatment.
Our ﬁndings suggest that nonresponders are associ-
ated with a constellation of preexisting factors. Initial
severity, greater use of emotional coping strategies, less
use of avoidance coping strategies, introversion, and less
emotional stability predicted nonresponder status rela-
tive to gradual or rapid responder status. These associ-
ations were above and beyond other coping strategies
and personality dimensions, underscoring the relative
salience of these factors predicting nonresponse. More-
over, nonresponders were more likely to present with a
co-occurring Axis II disorder. Our ﬁndings suggest that
assessment of these variables could assist in predicting
likely nonresponders, although future research is needed
to identify other salient risk factors associated with non-
response and how these can be modiﬁed to increase ef-
ﬁcacy in this group.
Our study has several limitations. First, we included
two types of antidepressants and three modalities of psy-
chotherapy, which limits the speciﬁcity of our ﬁndings.
The different types of treatments may include their own
unique types growth trajectories, which are not explored
in this study; however, since the treatment modalities
were not associated with growth class membership, it
seems unlikely that they would share markedly dissimi-
lar growth classes. Relatedly, psychotherapies were not
manualized or formally standardized that limits the ap-
plicability of these ﬁndings to standardized applications.
Second, our use of four time points is a relatively coarse
series of data points over 6 months. Studies exploring
weekly depression scores over 6 months or more may
unveil that certain growth classes are associated with
signiﬁcant between-session variability. Third, the drop-
ping out of patients and the exclusion of patients could
have conceivably inﬂuenced the results by preventing
the discovery of latent growth classes unique to these
subpopulations. Fourth, our use of unstructured inter-
views may have reduced the inter-rater reliability of the
diagnoses. Fifth, the current study did not include a self-
report inventory of symptoms, which could have offered
an alternative perspective of symptom severity and thus
strengthened our conclusions.
Our study supports that gradual responders, rapid re-
sponders, and nonresponders in depression treatments
represent classes that share qualitatively different growth
trajectories. Moreover, our study is the ﬁrst to demon-
strate qualitatively distinct growth trajectories in psy-
chotherapy outcomes. Predictingwhat patients are likely
to be nonresponders would be remarkably useful and we
demonstrate that nonresponder status is associated with
a constellation of preexisting personality features and
coping tendencies. Future research is needed to identify
what factors cause certain patients to experience min-
imal symptom reduction in treatment, and why others
get better after only a few weeks. Lastly, our use of a
longer time period relative to other studies in this area
highlights potential overestimates of nonresponders in
previous research. Indeed, our ﬁndings support the ef-
fectiveness of antidepressants and psychotherapy by sug-
gesting that the vast majority of patients experience at
least moderate improvement over 6 months of routine
treatment.
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